Lymphoma Clinical Trials in Detroit

Showing 641-641 of 641 trials

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

NCT00022932

The purpose of this study is to determine the safety and effectiveness of using Iodine-131 Anti-B1 Antibody for the treatment of patients with large B-cell non-Hodgkin's lymphoma (NHL) who have achieved a response following 6-8 cycles of CHOP therapy.

Non-Hodgkin's Lymphoma

Corixa CorporationStarted Jan 2000

Chicago, Illinois, United States • Boston, Massachusetts, United States • New York, New York, United States

PreviousPage 33 of 33

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

Lymphoma Trials in Other Cities

Other Conditions in Detroit